Citizens raises Intellia Therapeutics stock price target on FDA hold lift
#Intellia Therapeutics #FDA Clinical Hold #Stock Price Target #ATTR-CM #NASDAQ:NTLA #Analyst Ratings #Biotechnology Stocks #Pharmaceutical Trials
📌 Key Takeaways
- Citizens raised Intellia Therapeutics price target to $28 from $21
- FDA lifted clinical holds on Intellia's trials based on safety data from 650 patients
- Intellia's stock has surged 72% year-to-date, currently trading at $15.44
- Other analyst firms including RBC Capital and Chardan also adjusted their price targets
📖 Full Retelling
Citizens raised Intellia Therapeutics' stock price target to $28 from $21 on March 3, 2026, after the FDA lifted clinical holds on the company's trials based on efficacy and safety data from approximately 650 patients. The biotechnology firm's shares currently trade at $15.44, representing substantial upside potential according to the analyst firm, and have surged 72% year-to-date following the regulatory developments. Citizens maintained its Market Outperform rating for Intellia, with the new price target supported solely by Hereditary Angioedema (HAE) data expected this summer. The analyst from Citizens noted that the FDA must have perceived sufficient risk/reward benefits to reach its conclusion quickly regarding the clinical holds. The FDA had previously lifted a hold on the MAGNITUDE-2 trial in January, which investigates nex-z treatment for ATTR-PN patients, and subsequently removed the hold on the MAGNITUDE trial focused on the same treatment for ATTR-CM, a cardiomyopathy condition. The clinical holds were initially imposed after a serious liver toxicity event, making the FDA's recent decisions particularly significant for Intellia's ongoing trials and future prospects.
🏷️ Themes
Biotechnology, FDA Regulation, Stock Market Analysis, Pharmaceutical Trials
📚 Related People & Topics
Intellia Therapeutics
American biotechnology company
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietar...
Entity Intersection Graph
No entity connections available yet for this article.
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold dips, reverses course as stronger dollar weighs amid Iran conflict Oil extends surge on concerns surrounding Strait of Hormuz closure Futures drop, oil prices climb amid Iran conflict - what’s moving markets Gold price surge after Iran attack could fade, Pepperstone says FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Citizens raises Intellia Therapeutics stock price target on FDA hold lift By Investing.com Analyst Ratings Published 03/03/2026, 05:43 AM Citizens raises Intellia Therapeutics stock price target on FDA hold lift 0 NTLA 12.05% Investing.com - Citizens raised its price target on Intellia Therapeutics shares (NASDAQ:NTLA) to $28 from $21 while maintaining a Market Outperform rating. The stock currently trades at $15.44, suggesting substantial upside potential, and has surged 72% year-to-date. The FDA lifted a clinical hold on the company based on available efficacy and safety data from approximately 650 enrolled patients. The data remain blinded to Intellia Therapeutics. Citizens added back its valuation for ATTR in the updated price target. The firm said the $28 price target is supported by HAE alone. The analyst from Citizens stated the FDA must have seen some risk/reward benefit to reach its conclusion quickly. Citizens views the development as positive ahead of HAE data expected this summer. According to InvestingPro data, 5 analysts have revised their earnings upwards for the upcoming period, reinforcing the bullish sentiment. The platform offers deeper insights into NTLA’s financial health and comprehensive Pro Research Reports for smarter investment decisions. In other recent news, Intellia Therapeutics has seen significant developments following the FDA’s decision to lift clinical holds on its trials. The FDA removed the hold on the MAGNITUDE trial, which is focused on the nex-z treatment for ATTR-CM, a cardiomyopathy condition. This follows the earlier lifting of a hold on th...
Read full article at source